Answers are grounded in this paper and cite their sources.
Metformin and sodium-glucose-cotransporter-2 inhibitors (SGLT2i) are cornerstone therapies for managing hyperglycemia in diabetes. However, their detailed impacts on metabolic processes, particularly within the citric acid (TCA) cycle and its anaplerotic pathways, remain unclear. This study investigates the tissue-specific metabolic effects of metformin, both as a monotherapy and in combination with SGLT2i, on the TCA cycle and associated anaplerotic reactions in both mice and humans.
No takes yet. Share an insight, caveat, or question.
Harada et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: